SOURCE: King Pharmaceuticals, Inc.

King Pharmaceuticals, Inc.

March 19, 2010 09:46 ET

King Pharmaceuticals to Present at Barclays Capital Healthcare Conference

BRISTOL, TN--(Marketwire - March 19, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) today announced plans to provide a presentation on Wednesday, March 24, 2010, at 2:30 p.m. ET, at the Barclays Capital 2010 Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida. The presentation may include a discussion of the Company's marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business.

About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.

About Forward-looking Statements
This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the Company's scheduled presentation on March 24, 2010. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

EXECUTIVE OFFICES
KING PHARMACEUTICALS, INC.
501 FIFTH STREET, BRISTOL, TENNESSEE 37620

Contact Information

  • Contact:
    Jack Howarth, Vice President, Investor Relations
    908-429-8350